Janssen Announces Phase 2b Data Showing RSV Adult Vaccine Provides High Level of Protection against Lower Respiratory Infections in Older Adults

Janssen Announces Phase 2b Data Showing RSV Adult Vaccine Provides High Level of Protection against Lower Respiratory Infections in Older Adults

Janssen presented results from the phase 2b CYPRESS trial as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2. Results showed the RSV vaccine to be highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80% in adults aged 65 and older. The RSV vaccine also demonstrated an efficacy of 70% against any symptomatic RSV-associated acute respiratory infection (ARI) and elicited robust humoral and cellular immune responses. Participants in the immunogenicity subset showed a substantial increase in RSV neutralizing antibodies 14 days after vaccination. The RSV vaccine candidate was generally well-tolerated. 

Based on the positive results from the Phase 2b CYPRESS study, Janssen has initiated the global Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety, and immunogenicity of the adult RSV vaccine against LRTD caused by RSV, when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia, and the Southern Hemisphere....

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee